Page 1

gossamerbio Gossamer Bio Announces First Quarter 2021 Financial Results and Provides Corporate Update May 6 , 2021 - Seralutinib and GB004 continue to progress through ongoing Phase 2 TORREY and SHIFT - UC clinical trials for Pulmonary Arterial Hypertension ( PAH ) and Ulcerative Colitis ( UC ) , respectively- - Cash , cash equivalents and marketable securities totaled $ 453 million as of March 31 , 2021 - SAN DIEGO -- ( BUSINESS WIRE ) -- May 6 , 2021-- Gossamer Bio , Inc. ( Nasdaq : GOSS ) , a clinical - stage biopharmaceutical company focused on discovering , acquiring , developing and commercializing therapeutics in the disease areas of immunology , inflammation and oncology , today announced its financial results for the first quarter of 2021 and provided a corporate update . Clinical - Stage Product Candidate Updates Seralutinib ( GB002 ) : Inhaled PDGFR , CSF1R and C - KIT Inhibitor for PAH • Enrollment ongoing in the TORREY Study , a Phase 2 clinical trial in patients with PAH whose disease has progressed despite standard - of - care therapy . The primary endpoint is change in pulmonary vascular resistance ( PVR ) from baseline at week 24. Topline data from the TORREY study are expected in the first half of 2022 , subject to developments in the ongoing COVID - 19 pandemic . • Key opinion leader - led webcast and presentation regarding PAH and seralutinib held on December 15 , 2020 available through the " Events / Presentations ” page in the " Investors " section of the Company's website at www.gossamerbio.com . GB004 : Oral , Gut - Targeted HIF - 1a Stabilizer for Inflammatory Bowel Disease ( IBD ) • Enrollment ongoing in the SHIFT - UC Study , a Phase 2 clinical trial in patients with active UC despite treatment with 5 - ASAs . The primary endpoint is proportion of patients with clinical remission at week 12. Topline data from the SHIFT - UC study are expected in the first half of 2022 , subject to developments in the ongoing COVID - 19 pandemic . • Key opinion leader - led webcast and presentation regarding IBD and GB004 held on February 18 , 2021 available through the “ Events / Presentations " page in the " Investors " section of the Company's website at www.gossamerbio.com . GB1275 : Oral CD11b Modulator for Solid Tumor Oncology Indications • Enrollment ongoing in a Phase 1 expansion cohort studying the recommended Phase 2 dose in KEYNOTE - A36 , a Phase 1/2 clinical trial , including patients with gastric or esophageal cancer who have progressed after initial response to anti - PD - 1 therapy and patients with advanced MSS colorectal cancer . • Additional clinical data from the ongoing GB1275 Phase 1/2 will be presented at the American Society of Clinical Oncology ( ASCO ) 2021 Annual Meeting being held virtually from June 4 - 8 , 2021. Oral presentation details : o Abstract Number : 2505 • Abstract Title : Preliminary clinical and biologic results of GB1275 , a first - in - class oral CD11b modulator , alone and with pembrolizumab , in advanced solid tumors ( KEYNOTE - A36 ) • Session Title : Developmental Therapeutics - Immunotherapy • Session Date and Time : Monday , June 7 , 2021 from 3:00 pm - 6:00 pm ET Corporate Updates • Gossamer announced the promotion of Laura Carter , Ph.D. and Caryn Peterson to Chief Scientific Officer and Executive Vice President , Regulatory Affairs , respectively . Financial Results for the Quarter Ended March 31 , 2021 • Cash , Cash Equivalents and Marketable Securities : Cash , cash equivalents and marketable securities as of March 31 , 2021 , were $ 453.3 million . The Company expects the combination of current cash , cash equivalents and marketable securities , and access to its debt facility will be sufficient to fund its operating and capital expenditures into the second half of 2023 . • Research and Development ( R & D ) Expenses : For the quarter ended March 31 , 2021 , R & D expenses were $ 41.8